secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2023-01-23T23:59:59+00:00
Accession:  0001493152-23-002125
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow closes $130M acquisition of five branded ophthalmic products from Novartis
--------------------------------------------------------------------------------

- Paid $130M at closing for U.S. rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, TRIESENCE; up to $45M milestone for Triesence.
- Funded with $59.75M senior secured loan, stock sale ($22.6M net), $40.25M 11.875% notes due 2027, and cash.
- Expects ~6-month transition; Novartis continues selling, transfers net profit to Harrow; NDAs to transfer.
- Reaffirms 2023 guidance: net revenue $135-143M, adjusted EBITDA $44-50M; expects growth in 2024 and beyond.
- Products expected immediately accretive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315223002125/0001493152-23-002125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315223002125/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-002125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer